A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

Inclusion criteria

• Age 18 to 75 years of age
• acceptable FEV1 (according to ATS and ERS)
• compliance with study procedures All Asthma Cohorts
• physician diagnosed Asthma greater or equal to 3 months prior to screening visit

Exclusion criteria

• history of alcohol or drug abuse within the past year
• pregnant at time of an assessment
• has an altered mental status at the time of informed consent
• receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
• history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
• terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
• Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.